SCS-90: Spinal Cord Stimulation for Restoration of Function in Lower-Limb Amputees, 90-Day

Sponsor
Lee Fisher, PhD (Other)
Overall Status
Recruiting
CT.gov ID
NCT04547582
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS) (NIH)
10
1
1
103.5
0.1

Study Details

Study Description

Brief Summary

The goals of this study are to provide sensory information to amputees and reduce phantom limb pain via electrical stimulation of the lumbar spinal cord and spinal nerves. The spinal nerves convey sensory information from peripheral nerves to higher order centers in the brain. These structures still remain intact after amputation and electrical stimulation of the dorsal spinal nerves in individuals with intact limbs and amputees has been demonstrated to generate paresthetic sensory percepts referred to portions of the distal limb. Further, there is recent evidence that careful modulation of stimulation parameters can convert paresthetic sensations to more naturalistic ones when stimulating peripheral nerves in amputees. However, it is currently unclear whether it is possible to achieve this same conversion when stimulating the spinal nerves, and if those naturalistic sensations can have positive effects on phantom limb pain. As a first step towards those goals, in this study, the investigators will quantify the sensations generated by electrical stimulation of the spinal nerves, study the relationship between stimulation parameters and the quality of those sensations, measure changes in control of a prosthesis with sensory stimulation, and quantify the effects of that stimulation on the perception of the phantom limb and any associated pain.

Condition or Disease Intervention/Treatment Phase
  • Device: Spinal cord stimulator
N/A

Detailed Description

During the study, FDA-cleared spinal cord stimulator leads will be placed in the lumbar epidural space of lower limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance. This approach is essentially identical to the FDA-cleared procedure in which these devices are placed in the lumbar epidural space for treatment of intractable low back and leg pain. In that procedure, it is common clinical practice to place 2-3 leads temporarily in the epidural space through a percutaneous approach and perform a multiday trial to determine if the patient experiences any pain reduction from spinal cord stimulation. Following the trial, the percutaneous leads are surgically removed, and the patient is referred to a neurosurgeon for permanent surgical implantation.

Similarly, in this study, the device will be tunneled percutaneously through the skin and anchored in place. Using the stylet included with the spinal cord stimulator leads, the devices will be steered laterally under fluoroscopic guidance to target the dorsal spinal nerves. During lab experiments, the leads will be connected to an external stimulator. In this study, the devices will remain in the epidural space for up to 90 days and will be surgically removed. Throughout the study, the investigators will perform a series of psychophysical evaluations to characterize the sensory percepts evoked by epidural stimulation, along with functional evaluations of the effects of stimulation on the ability to control a prosthetic limb. In addition, the investigators will perform surveys to characterize changes in phantom limb sensation and pain that occur during stimulation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
10 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Spinal Cord Stimulation for Restoration of Function in Lower-Limb Amputees, 90-Day
Actual Study Start Date :
Dec 16, 2016
Anticipated Primary Completion Date :
Aug 1, 2024
Anticipated Study Completion Date :
Aug 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Spinal cord stimulation

Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation. Participants in this study receive spinal cord stimulation will be trans-tibial amputees that are at least six month post--amputation. Subjects will have varying levels of phantom limb sensation and pain, but should have no other significant neurological disorders.

Device: Spinal cord stimulator
Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.

Outcome Measures

Primary Outcome Measures

  1. Number of participants experiencing serious device-related adverse events up to 90 days following implantation [90 days]

    Investigators will track the number of participants experiencing serious device-related adverse events, such as unresolved superficial infection resulting in lead removal, deep infection, inpatient hospitalization, withdrawal from the study due to worsening pain or intolerable dysesthesia, or fracture due to falls related to the study interventions, that occur during the course of and up to 90 days following implantation.

  2. Location of evoked sensory percepts [90 days]

    Document where on the body the subject perceives the stimulation locations.

  3. Stimulation perceptual thresholds to a variety of stimulus parameters [90 days]

    Quantify the threshold (minimum charge and pulse rate) stimulus required to evoke sensory percepts during epidural spinal nerve stimulation.

  4. Stimulation neurophysiology thresholds to a variety of stimulus parameters [90 days]

    Quantify the threshold (minimum charge and pulse rate) stimulus required to evoke neurophysiological responses during epidural spinal nerve stimulation

Secondary Outcome Measures

  1. Change in phantom limb pain using the McGill Pain Questionnaire [90 days]

    The McGill Pain Questionnaire is a questionnaire used to evaluate the severity of pain experienced by the participant. The questionnaire is scaled, with a minimum and maximum pain score of 0 and 78, respectively. The higher the score on the questionnaire, the more intense the pain felt by the participant. A lower score would therefore represent a decrease in experienced phantom limb pain. Before placement of the spinal cord stimulator leads, investigators will document the subject's description of their history of perceived phantom limb. Investigators will ask them to periodically update their perception of the limb throughout experimental sessions, as well as within a month after the device has been removed.

  2. Qualitative self-report of evoked sensations [90 days]

    Document the subjective perception of lumbosacral epidural spinal nerve stimulation for restoration of sensation. The investigators will ask each subject to provide subjective feedback on their perceived utility of the sensory feedback provided by the device.

  3. Ability to use a prosthetic limb with neural signals [90 days]

    Investigators will test the subject's success rate during control of prosthetic limb with and without sensory feedback provided by electrical stimulation of the spinal roots. Using either a virtual prosthetic limb or an instrumented prosthesis, stimulation of the spinal roots will be modulated based on signals recorded from the limb.

Eligibility Criteria

Criteria

Ages Eligible for Study:
22 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Subjects must have an amputation of one lower limb, at a level between the ankle and knee joints. Minor amputation of the contralateral limb (i.e. toes or partial foot) is not exclusionary.

  2. Subjects must be over 6 months post-amputation at the time of lead placement.

  3. Subjects must be between the ages of 22 and 70 years old. Participants outside this age range may be at an increased medical risk and have an increased risk of fatigue during testing.

Exclusion Criteria:
  1. Subjects must not have any serious disease or disorder that could affect their ability to participate in this study.

  2. Female subjects of childbearing age must not be pregnant or breast-feeding.

  3. Subjects must not be receiving medications that affect blood coagulation.

  4. Subjects must not have an allergy to contrast medium or renal failure that could be exacerbated by the contrast agent used in MRIs. For this study, renal insufficiency will be determined through blood work and defined as BUN of 30 or less and Creatinine of 1.5 or less.

  5. Subjects may not have a hemoglobin A1c level above 8.0 mg/dl at time of implant.

  6. Subjects may not have any implanted medical devices that are not cleared for MRI.

  7. Subjects with a T-Score higher than 63 on the 18-question Brief Symptoms Inventory (BSI-18) who have undergone discussions with and been deemed unsuitable by the Principal Investigator, a study physician, and a psychologist

  8. Subjects may not have a cardiac pacemaker.

  9. Subjects may not have a cardioverter defibrillator.

  10. Subjects may not be currently receiving diathermy therapy.

  11. Subjects may not have an implanted infusion pump.

  12. Subjects may not be immunosuppressed or currently receiving immunosuppressive medications.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Pittsburgh Pittsburgh Pennsylvania United States 15213

Sponsors and Collaborators

  • Lee Fisher, PhD
  • National Institute of Neurological Disorders and Stroke (NINDS)

Investigators

  • Principal Investigator: Lee E Fisher, PhD, University of Pittsburgh

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Lee Fisher, PhD, Assistant Professor, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT04547582
Other Study ID Numbers:
  • STUDY19010019
  • 1UH3NS100541-01A1
First Posted:
Sep 14, 2020
Last Update Posted:
Jan 10, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Keywords provided by Lee Fisher, PhD, Assistant Professor, University of Pittsburgh
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 10, 2022